Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update And Relaunches With Name Change From Psioxus Therapeutics
Amount Raised
$30 Million
Round Type
Funding Round
Investors
Description
Akamis Bio (formerly PsiOxus Therapeutics), a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced a $30 million convertible note financing co-led by a group of leading US life science investors. In addition, the company provided a progress update on its clinical pipeline programs, NG-350A and NG-641, while announcing a relaunch of the company as Akamis Bio building upon its ongoing corporate transformation. In conjunction with the corporate name change, the company has launched a new website at www.akamisbio.com.
Quick answer
Akamis Bio raised $30 Million in a Funding Round round, dated January 5, 2023. Investors: Westlake Village Bio Partners and ARCH Venture Partners.
- How much did Akamis Bio raise?
- Akamis Bio raised $30 Million in a Funding Round round on January 5, 2023.
- Who invested in Akamis Bio?
- Westlake Village Bio Partners and ARCH Venture Partners are named as investors in this round.
- What does Akamis Bio do?
- Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer.
- Who are the decision-makers at Akamis Bio?
- Fundz holds 1 contact at Akamis Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Akamis Bio that raised within 45 days of this round, from Fundz verified event records.
- Chroma Medicine raised $135M on February 8, 2023.
- Solid Biosciences raised $9.2M on December 2, 2022.
- iECURE raised $65M (Funding Round) on November 30, 2022.
- Pathos AI raised $20M on February 17, 2023.
- Alpha Cognition raised $1.8M (Seed) on February 16, 2023.
- Disc raised $63M (Funding Round) on February 14, 2023.
Who to call at Akamis Bio, and when
A new round usually means Akamis Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Akamis Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Akamis Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Akamis Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Akamis Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Akamis Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.